Company Valuation: Northwest Biotherapeutics, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2024 2025 2026 2027
Market Cap 1 364 358.4 258.9 -
Change - -1.53% -27.76% -
Enterprise Value (EV) 1 364 358.4 355 383.8
Change - -1.53% -0.95% 8.13%
P/E -3.92x -5.72x - -
PBR - - - -
PEG - 0.1x - -
Capitalization / Revenue - - - 6.65x
EV / Revenue - - - 9.86x
EV / EBITDA - - - -
EV / EBIT - - -5.27x -8.1x
EV / FCF - - -6.96x -9.42x
FCF Yield - - -14.4% -10.6%
Dividend per Share 2 - - - -
Rate of return - - - -
EPS 2 -0.07 -0.04 - -
Distribution rate - - - -
Net sales 1 - - - 38.93
EBITDA - - - -
EBIT 1 - - -67.3 -47.4
Net income -85.19 -61.48 - -
Net Debt 1 - - 96.08 124.9
Reference price 2 0.2748 0.2288 0.1451 0.1451
Nbr of stocks (in thousands) 13,24,666 15,66,728 17,84,345 -
Announcement Date 31/03/25 15/04/26 - -
1USD in Million2USD
Estimates

P/E, Detailed evolution



P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
- - - - 26Cr
17.32x6.64x12.72x1.72% 6.64TCr
31.83x8.5x28.08x0.07% 5.89TCr
38.41x6.84x20.46x0.85% 5.52TCr
44.35x6.2x29.52x-.--% 4.72TCr
33.62x3.22x13.9x-.--% 4.25TCr
35.98x8.9x23.21x0.36% 3.64TCr
-19.28x55.7x-21.11x-.--% 3.52TCr
41.59x8.02x26.91x-.--% 3.27TCr
-74.36x14.09x-75.73x-.--% 2.67TCr
Average 16.61x 13.12x 6.44x 0.33% 4TCr
Weighted average by Cap. 21.61x 11.64x 11.39x 0.44%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Northwest Biotherapeutics, Inc.

Historical PBR trend

Valuation ratios - PBR - Northwest Biotherapeutics, Inc.

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Northwest Biotherapeutics, Inc.

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Northwest Biotherapeutics, Inc.

  1. Stock Market
  2. Stocks
  3. NWBO Stock
  4. Valuation Northwest Biotherapeutics, Inc.